Barbara Pro

Professor, Medicine, Hematology Oncology Division

Emailbarbara.pro@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Clinical trials

Training Experience

1995	Internship, Mount Sinai Hospital, New York
1996	Residency, Mount Sinai Hospital, New York

Education/Academic qualification

MD, University of Rome "La Sapienza"

… → 1988

Medicine, MD, University of Rome La Sapienza

… → 1988

Research interests

Blood Cancer (leukemia and lymphomas)
Clinical Research

Fingerprint

Dive into the research topics where Barbara Pro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

15 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

6 Active
7 Finished

Prot #NU MSK19H03: A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)
Pro, B.
Memorial Sloan-Kettering Cancer Center
9/17/20 → 9/17/23
Project: Research project
Prot #ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
Pro, B.
Astex Pharmaceuticals, Inc.
10/17/18 → 10/17/21
Project: Research project
Prot #VS-0145-225: A Muti-Center, Phase 2, Open Label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Pro, B.
Parexel, Verastem, Inc.
8/6/18 → 8/6/21
Project: Research project
Prot #X16042: A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Pro, B.
Millennium Pharmaceuticals, Inc
6/1/15 → 6/1/21
Project: Research project
Prot #RV-CL-PTCL-PI-003974: NU 14H04: Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL
Pro, B.
Celgene Corporation
5/14/15 → 5/14/21
Project: Research project

9272 Citations
123 Article
24 Review article
6 Letter
4 Comment/debate
More
- 1 Editorial

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma
Samaniego, F., McLaughlin, P., Neelapu, S. S., Feng, L., Fanale, M., Nastoupil, L., Rodriguez, M. A., Pro, B., Taylor, E., Hagemeister, F. B. & Fowler, N., 2021, In: Leukemia and Lymphoma. 62, 1, p. 58-67 10 p.
Research output: Contribution to journal › Article › peer-review
Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides
Walker, C. J., Donnelly, E. D., Moreira, J., Mehta, J., Mittal, B. B., Choi, J., Zhou, X. A., Guitart, J. & Pro, B., Jan 2021, In: JAAD Case Reports. 7, p. 87-90 4 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas
Daniels, J., Doukas, P. G., Escala, M. E. M., Ringbloom, K. G., Shih, D. J. H., Yang, J., Tegtmeyer, K., Park, J., Thomas, J. J., Selli, M. E., Altunbulakli, C., Gowthaman, R., Mo, S. H., Jothishankar, B., Pease, D. R., Pro, B., Abdulla, F. R., Shea, C., Sahni, N., Gru, A. A. & 4 others, Pierce, B. G., Louissaint, A., Guitart, J. & Choi, J., Dec 1 2020, In: Nature communications. 11, 1, 1806.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Diagnosis, Risk Stratification, and Treatment of Peripheral T-Cell Lymphomas: Past and Present
Pearse, W. B. & Pro, B., May 1 2020, In: Cancer journal (Sudbury, Mass.). 26, 3, p. 253-259 7 p.
Research output: Contribution to journal › Article › peer-review
Hepatosplenic T-cell lymphoma: A rare but challenging entity
Pro, B., Allen, P. & Behdad, A., Oct 29 2020, In: Blood. 136, 18, p. 2018-2026 9 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
1 Scopus citations